Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer

Brizel, David M.; Albers, Mary; Fisher, Samuel R.; Scher, Richard L.; Richtsmeier, William J.; Hárs, Vera; George, Stephen L.; Huang, Andrew T.; Prosnitz, Leonard R.

doi:10.1056/nejm199806183382503

Cited by 1,049 publications

(524 citation statements)

References 26 publications

Supporting

Mentioning

478

Contrasting

Unclassified

Order By: Relevance

“…In recent controlled studies, PF-based chemoradiation regimens, used as induction or definitive therapy, have demonstrated improved efficacy compared with conventional or hyperfractionated radiotherapy alone in locally advanced SCCHN (Vokes et al, 1995;Brizel et al, 1998). The activity of docetaxel in SCCHN, coupled with the drug's in vitro radiosensitizing properties (Creane et al, 1999;Mason et al, 1999;Pradier et al, 2001), provide the basis for clinical trials with docetaxel as a component of concurrent or alternating chemoradiation in locally advanced SCCHN (Koukourakis et al, 1999;Hesse et al, 2000;Tishler et al, 2002).…”

Section: Docetaxel-based Chemoradiation Regimens For Locally Advancedmentioning

confidence: 99%

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin -5-fluorouracil (5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination with PF regimens as induction therapy. The results of six phase II studies of docetaxel -PF regimens (TPF) as induction in locally advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were demonstrated across the phase II trials in the range 42 -82 and 71 -100%, respectively. The toxicity profile seen with TPF-based regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy.

show abstract

Section: Docetaxel-based Chemoradiation Regimens For Locally Advancedmentioning

confidence: 99%

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In CRT trials the acute mortality is described in the range from 2% [5] to 9.3% [6]. Infection is one of the main causes of acute mortality [6,7].…”

Section: Introductionmentioning

confidence: 99%

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus

Mirabile

Numico²,

Russi

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a review of recent literature in these topics

show abstract

“…The cisplatin/5-fluorouracil (5-FU) regimen is considered to be a standard chemotherapy regimen in the treatment of advanced HNC as part of an organ-conserving strategy (Taylor et al, 1997;Brizel et al, 1998;Calais et al, 1999). Another standard treatment is the combination of external beam radiation therapy with surgical extirpation (Bensadoun et al, 1998;Fu et al, 2000;Vokes et al, 2000).…”

mentioning

confidence: 99%

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer

et al. 2002

View full text Add to dashboard Cite

Elevated levels of epidermal growth factor receptor in head and neck cancer have been extensively reported, and are correlated with poor prognosis. The combination of cisplatin and 5-fluorouracil is a standard treatment regimen for head and neck cancer, with radiation representing another therapeutic option. Six head and neck cancer cell lines were used to study the cytotoxic effects of combining ZD1839 ('Iressa'), a new selective epidermal growth factor receptor tyrosine kinase inhibitor, and radiation. Two of the cell lines were also used to study the combination of ZD1839 and cisplatin/5-fluorouracil. Cytotoxic effects were assessed by the MTT test. The results indicated that ZD1839 applied before radiation gave the best effects (P=0.002); an effect that was strongest in those p53-mutated cell lines that express the highest epidermal growth factor receptor levels. The effects of ZD1839 with cisplatin and/or 5-fluorouracil were sequence dependent (P50

show abstract

Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer

Abstract: Combined treatment for advanced head and neck cancer is more efficacious and not more toxic than hyperfractionated irradiation alone.

Cited by 1,049 publications

References 26 publications

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer

Contact Info

Product

Resources

About